153 related articles for article (PubMed ID: 31756547)
1. Preoperative chemotherapy compared with postoperative adjuvant chemotherapy for squamous cell carcinoma of the thoracic oesophagus with the detection of circulating tumour cells randomized controlled trial.
Zhao Y; Han L; Zhang W; Shan L; Wang Y; Song P; Peng C; Zhao X
Int J Surg; 2020 Jan; 73():1-8. PubMed ID: 31756547
[TBL] [Abstract][Full Text] [Related]
2. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
3. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
4. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
[TBL] [Abstract][Full Text] [Related]
6. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
Qin RQ; Wen YS; Wang WP; Xi KX; Yu XY; Zhang LJ
Med Oncol; 2016 Apr; 33(4):31. PubMed ID: 26922662
[TBL] [Abstract][Full Text] [Related]
7. Postoperative Chemotherapy for Thoracic Pathological T3N0M0 Esophageal Squamous Cell Carcinoma.
Wang Q; Peng L; Li T; Dai W; Jiang Y; Xie T; Fang Q; Wang Y; Wu L; Cao B; Han Y; Lang J
Ann Surg Oncol; 2020 May; 27(5):1488-1495. PubMed ID: 31974708
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma.
Han L; Li YJ; Zhang WD; Song PP; Li H; Li S
Medicine (Baltimore); 2019 Feb; 98(6):e13921. PubMed ID: 30732126
[TBL] [Abstract][Full Text] [Related]
10. Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial.
Tachibana M; Yoshimura H; Kinugasa S; Shibakita M; Dhar DK; Ueda S; Fujii T; Nagasue N
Eur J Surg Oncol; 2003 Sep; 29(7):580-7. PubMed ID: 12943623
[TBL] [Abstract][Full Text] [Related]
11. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1).
Li C; Zhao S; Zheng Y; Han Y; Chen X; Cheng Z; Wu Y; Feng X; Qi W; Chen K; Xiang J; Li J; Lerut T; Li H
Eur J Cancer; 2021 Feb; 144():232-241. PubMed ID: 33373868
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of detecting circulating tumor cells in patients with esophageal squamous cell carcinoma by EpCAM‑independent enrichment and immunostaining‑fluorescence in situ hybridization.
Zhang Y; Li J; Wang L; Meng P; Zhao J; Han P; Xia J; Xu J; Wang L; Shen F; Zheng A; Zhou F; Fan R
Mol Med Rep; 2019 Aug; 20(2):1551-1560. PubMed ID: 31257510
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Lyu X; Huang J; Mao Y; Liu Y; Feng Q; Shao K; Gao S; Jiang Y; Wang J; He J
J Surg Oncol; 2014 Dec; 110(7):864-8. PubMed ID: 24976079
[TBL] [Abstract][Full Text] [Related]
14. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
Wang WT; Guo CQ; Cui GH; Zhao S
World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
[TBL] [Abstract][Full Text] [Related]
15. Postoperative adjuvant chemotherapy versus chemoradiotherapy for node-positive esophageal squamous cell carcinoma: a propensity score-matched analysis.
Wang Q; Lang J; Li T; Peng L; Dai W; Jiang Y; Xie T; Fang Q; Wang Y; Wu L; Cao B; Han Y
Radiat Oncol; 2020 May; 15(1):119. PubMed ID: 32448253
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Ando N; Kato H; Igaki H; Shinoda M; Ozawa S; Shimizu H; Nakamura T; Yabusaki H; Aoyama N; Kurita A; Ikeda K; Kanda T; Tsujinaka T; Nakamura K; Fukuda H
Ann Surg Oncol; 2012 Jan; 19(1):68-74. PubMed ID: 21879261
[TBL] [Abstract][Full Text] [Related]
17. Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients.
Meng P; Wei J; Geng Y; Chen S; Terpstra MM; Huang Q; Zhang Q; Su Z; Yu W; Su M; Kok K; van den Berg A; Gu J
BMC Cancer; 2019 Aug; 19(1):818. PubMed ID: 31429737
[TBL] [Abstract][Full Text] [Related]
18. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
[TBL] [Abstract][Full Text] [Related]
19. Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients.
Sohda M; Saito H; Kuriyama K; Yoshida T; Kumakura Y; Honjyo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Sakai M; Miyazaki T; Fukuchi M; Kuwano H
In Vivo; 2019; 33(2):501-506. PubMed ID: 30804133
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.
Wang X; Wang H; Wang H; Huang J; Wang X; Jiang Z; Tan L; Jiang D; Hou Y
BMC Cancer; 2021 Feb; 21(1):111. PubMed ID: 33535987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
